AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9416712 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool-sevoflurane
Number of subjects: 63
Study 9416712 — intervention group
Group type: COMPARATOR
Intervention: Preschool-halothane
Number of subjects: 63
Study 9416712 — intervention group
Group type: COMPARATOR
Intervention: School-sevoflurane
Number of subjects: 63
Study 9416712 — intervention group
Group type: COMPARATOR
Intervention: School-halothane
Number of subjects: 63
Study 8119050 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline concentration of 10 mg/L
Number of subjects: 174
Study 8119050 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline concentration of 20 mg/L
Number of subjects: 174
Study 8119050 — intervention group
Group type: COMPARATOR
Intervention: No theophylline
Number of subjects: 174
Study 3687315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental 400)
Number of subjects: 21
Study 3687315 — intervention group
Group type: COMPARATOR
Intervention: Conventional antihypertensive therapy
Number of subjects: 21
Study 29363365 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Number of subjects: 1400
Study 29363365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 27461547 — intervention group
Group type: EXPERIMENTAL
Intervention: 14mg nicotine patch
Number of subjects: 52
Study 27461547 — intervention group
Group type: COMPARATOR
Intervention: placebo patch
Number of subjects: 52
Study 24892144 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 1041
Study 24892144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 1041
Study 24892144 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 1041
Study 24892144 — intervention group
Group type: COMPARATOR
Intervention: Additional controller medications
Number of subjects: 1041
Study 24892144 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary function
Number of subjects: 1041
Study 23761646 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in n3 PUFAs (3.5% of energy intake)
Number of subjects: 24
Study 23761646 — intervention group
Group type: COMPARATOR
Intervention: Control diet (0.5% of energy intake from n3 PUFAs)
Number of subjects: 24
Study 20639852 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023
Number of subjects: 0
Study 20639852 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 20639852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18724650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin 0.04% microsphere gel (TMG)
Number of subjects: 0
Study 18724650 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.3% gel
Number of subjects: 0
Study 18724650 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025% cream
Number of subjects: 0
Study 15917019 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation for 6 months
Number of subjects: 220
Study 15917019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 14584976 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects categorized and located in the same quadrant of the box
Number of subjects: 0
Study 14584976 — intervention group
Group type: COMPARATOR
Intervention: Objects randomly paired with locations
Number of subjects: 0
Study 11296072 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella vaccine
Number of subjects: 0
Study 11296072 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 0
Study 10215313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1
Number of subjects: 5
Study 10215313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 micrograms kg‐1
Number of subjects: 5
Study 10215313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms kg‐1
Number of subjects: 5
Study 10215313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 40 micrograms kg‐1
Number of subjects: 5
Study 10215313 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 5
Study 7533226 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.2-0.4 mg daily
Number of subjects: 2000
Study 7533226 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 2000
Study 3280266 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg cefuroxime (single intravenous injection)
Number of subjects: 40
Study 3280266 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg cefuroxime (three doses)
Number of subjects: 40
Study 3280266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftazidime (single intravenous injection)
Number of subjects: 40
Study 3280266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ceftazidime (three doses)
Number of subjects: 40
Study 31423576 — intervention group
Group type: COMPARATOR
Intervention: m7-FLIPI risk groups
Number of subjects: 95
Study 31423576 — intervention group
Group type: EXPERIMENTAL
Intervention: EZH2 mutations
Number of subjects: 95
Study 31423576 — intervention group
Group type: EXPERIMENTAL
Intervention: EP300 mutations
Number of subjects: 95
Study 29459361 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Number of subjects: 1443
Study 29459361 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 1443
Study 27159073 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 138
Study 27159073 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based training
Number of subjects: 138
Study 27159073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 138
Study 27159073 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medicine (EM) physicians
Number of subjects: 138
Study 25706751 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/day of D₃
Number of subjects: 60
Study 25706751 — intervention group
Group type: EXPERIMENTAL
Intervention: 7000 IU/day of D₃
Number of subjects: 60
Study 25706751 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study 24385632 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained African American participants
Number of subjects: 0
Study 24385632 — intervention group
Group type: COMPARATOR
Intervention: Untrained White participants
Number of subjects: 0
Study 20518169 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 60
Study 20518169 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 60
Study 19025521 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 4 days
Number of subjects: 12
Study 19025521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16522657 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg b.i.d. the day before surgery and 600 mg b.i.d. after; administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Number of subjects: 42
Study 16522657 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) administered p.o. for 24 h before operation and maintained i.v. for 48 h after operation.
Number of subjects: 42
Study 16522657 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) group.
Number of subjects: 42
Study 16522657 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo) group.
Number of subjects: 42
Study 14653289 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine Original [AP] (alcohol‐containing essential oil/phenolic compound mouthrinse)
Number of subjects: 54
Study 14653289 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Chloropharm [AC] (alcohol‐containing chlorhexidine mouthrinse)
Number of subjects: 54
Study 14653289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B Sensitive [PF] (phosphoric acid containing fluoride mouthrinse)
Number of subjects: 54
Study 14653289 — intervention group
Group type: COMPARATOR
Intervention: Distilled water [WC] (control)
Number of subjects: 54
Study 14653289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B Tooth & Gum Care [AF] (alcohol‐containing fluoride mouthrinse)
Number of subjects: 54
Study 14653289 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B Tooth & Gum Care Alcohol Free [OF] (alcohol free fluoride mouthrinse)
Number of subjects: 54
Study 11183627 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians' attitudes towards recruitment in randomised trials
Number of subjects: 20
Study 11183627 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to recruitment
Number of subjects: 20
Study 8826981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide treatment
Number of subjects: 20
Study 8826981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1590581 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropore filter
Number of subjects: 32
Study 1590581 — intervention group
Group type: COMPARATOR
Intervention: No Micropore filter (Control)
Number of subjects: 32
Study 30924958 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐based Treatment for ARFID (FBT‐ARFID)
Number of subjects: 28
Study 30924958 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 28
Study 28861202 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopically guided suprascapular nerve block and blinded axillary nerve block (10 mL 0.25% ropivacaine)
Number of subjects: 40
Study 28861202 — intervention group
Group type: COMPARATOR
Intervention: Blinded suprascapular nerve block (10 mL 0.25% ropivacaine)
Number of subjects: 40
Study 26513517 — intervention group
Group type: EXPERIMENTAL
Intervention: ST + EX (smoking cessation treatment plus exercise intervention)
Number of subjects: 136
Study 26513517 — intervention group
Group type: COMPARATOR
Intervention: ST + CTRL (smoking cessation treatment plus wellness education control)
Number of subjects: 136
Study 25155146 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg subcutaneous once weekly
Number of subjects: 310
Study 25155146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 22733291 — intervention group
Group type: EXPERIMENTAL
Intervention: Canaloplasty with cataract surgery (group K+P)
Number of subjects: 63
Study 22733291 — intervention group
Group type: COMPARATOR
Intervention: Canaloplasty alone (group K)
Number of subjects: 63
Study 20444749 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (group 1)
Number of subjects: 0
Study 20444749 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus placebo (group 2)
Number of subjects: 0
Study 20444749 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg plus methotrexate (group 3)
Number of subjects: 0
Study 20444749 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg plus methotrexate (group 4)
Number of subjects: 0
Study 17383857 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 200 mg/day)
Number of subjects: 51
Study 17383857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 16274377 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Prescription physical activity counseling program
Number of subjects: 270
Study 16274377 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study 12087138 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of lansoprazole daily
Number of subjects: 123
Study 12087138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 10803269 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR with HPV primers MY09‐MY11
Number of subjects: 174
Study 10803269 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR using a mixture of two pairs of primers bglobin PG04‐GH20 and HPV MY09‐MY11
Number of subjects: 174
Study 10803269 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR with human bglobin primers PG04‐GH20
Number of subjects: 174
Study 10803269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PCR testing
Number of subjects: 174
Study 8551824 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation alone
Number of subjects: 100
Study 8551824 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (50 micrograms intravenous bolus injection followed by intravenous infusion at 50 micrograms per h for 5 days) plus endoscopic variceal ligation
Number of subjects: 100
Study 2182204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg.kg‐1/hr with alfentanil infusion
Number of subjects: 30
Study 2182204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1/hr with alfentanil infusion
Number of subjects: 30
Study 2182204 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 4 mg.kg‐1/hr with alfentanil infusion
Number of subjects: 30
Study 2182204 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 7202816 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 20
Study 7202816 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 20
Study 31559204 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CRT)
Number of subjects: 40
Study 31559204 — intervention group
Group type: COMPARATOR
Intervention: Concomitant boost radiotherapy (CBRT)
Number of subjects: 40
Study 28715459 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 154
Study 28715459 — intervention group
Group type: COMPARATOR
Intervention: Sham abdominal acupuncture
Number of subjects: 154
Study 25581313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (detailed explanation, written report for physician, follow-up contacts at 2 and 4 months)
Number of subjects: 101
Study 25581313 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 101
Study 25581313 — intervention group
Group type: COMPARATOR
Intervention: Basic/control intervention (informed about diabetes risk factors and blood test result, advised to see a physician)
Number of subjects: 101
Study 21816963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 44
Study 21816963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 44
Study 21816963 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 44
Study 21791041 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical exercise programme (PEP) - instructed to exercise at least five times a week for at least 30 minutes per day
Number of subjects: 102
Study 21791041 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the GP
Number of subjects: 102
Study 21791041 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical exercise programme (PEP)
Number of subjects: 102
Study 19453961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600-1,800 mg per day)
Number of subjects: 73
Study 19453961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 19453961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 73
Study 17404825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified LDL-C lowering therapy with ezetimibe
Number of subjects: 400
Study 17404825 — intervention group
Group type: COMPARATOR
Intervention: HDL-C raising therapy with extended-release niacin
Number of subjects: 400
Study 14697441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx) 400 mg, 3 times daily during radiotherapy
Number of subjects: 40
Study 14697441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Ptx)
Number of subjects: 40
Study 11416076 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 207
Study 11416076 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Number of subjects: 207
Study 11416076 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy
Number of subjects: 207
Study 11416076 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger trials published more recently in Medline and in English language
Number of subjects: 207
Study 9404250 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg and trimetazidine 60 mg
Number of subjects: 64
Study 7683868 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical splanchnicectomy with alcohol
Number of subjects: 137
Study 7683868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injection)
Number of subjects: 137
Study 3500642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 mg daily)
Number of subjects: 37
Study 3500642 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (3.6 g daily)
Number of subjects: 37
Study 3500642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 3500642 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 37
Study 29601981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 0
Study 29601981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 28088674 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based computer intervention targeting substance use and treatment initiation
Number of subjects: 113
Study 25639980 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD intervention targeting self-efficacy with procedural and sensory information
Number of subjects: 83
Study 25639980 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital information leaflet (control)
Number of subjects: 83
Study 23836550 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation condition (observer is also the recipient of donations)
Number of subjects: 39
Study 23836550 — intervention group
Group type: COMPARATOR
Intervention: No motivation condition (observer is just observing)
Number of subjects: 39
Study 22007015 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention using the 5 A's model and cognitive‐behavioral techniques
Number of subjects: 1068
Study 22007015 — intervention group
Group type: COMPARATOR
Intervention: Information‐attention control condition
Number of subjects: 1068
Study 18079034 — intervention group
Group type: EXPERIMENTAL
Intervention: core‐build‐up resin
Number of subjects: 216
Study 18079034 — intervention group
Group type: COMPARATOR
Intervention: conventional luting cement
Number of subjects: 216
Study 18079034 — intervention group
Group type: EXPERIMENTAL
Intervention: tribochemical pretreatment of the post
Number of subjects: 216
Study 18079034 — intervention group
Group type: EXPERIMENTAL
Intervention: dual‐curing bonding system
Number of subjects: 216
Study 18079034 — intervention group
Group type: EXPERIMENTAL
Intervention: none, dual‐curing bonding, light‐curing bonding (for root dentin pretreatment)
Number of subjects: 216
Study 18079034 — intervention group
Group type: EXPERIMENTAL
Intervention: different regions of the root
Number of subjects: 216
Study 16782926 — intervention group
Group type: EXPERIMENTAL
Intervention: Very accelerated radiation therapy (62 to 64 Gy in 31 to 32 fractions of 2 Gy over 22 to 23 days)
Number of subjects: 268
Study 16782926 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy (70 Gy in 7 weeks, 35 fractions of 2 Gy over 49 days)
Number of subjects: 268
Study 16782926 — intervention group
Group type: EXPERIMENTAL
Intervention: Very accelerated radiation therapy
Number of subjects: 268
Study 16782926 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy
Number of subjects: 268
Study 12511310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (0.6 mg/kg)
Number of subjects: 96
Study 12511310 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (0.6 mg/kg)
Number of subjects: 96
Study 10994801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral MRI in solvent-exposed workers
Number of subjects: 36
Study 10994801 — intervention group
Group type: COMPARATOR
Intervention: Cerebral MRI in referents with no former solvent exposure
Number of subjects: 36
Study 9062855 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable barriers (Polyglactin 910)
Number of subjects: 20
Study 9062855 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable barriers (ePTFE)
Number of subjects: 20
Study 8445359 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper cervical adjustments (C2)
Number of subjects: 0
Study 8445359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cervical adjustments (C7)
Number of subjects: 0
Study 8445359 — intervention group
Group type: COMPARATOR
Intervention: Upper cervical sham manipulation
Number of subjects: 0
Study 3526208 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 47
Study 3526208 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 47
Study 30550987 — intervention group
Group type: EXPERIMENTAL
Intervention: Static illustrations with music/sounds
Number of subjects: 99
Study 30550987 — intervention group
Group type: EXPERIMENTAL
Intervention: Static illustrations without music/sounds
Number of subjects: 99
Study 30550987 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated illustrations with music/sounds
Number of subjects: 99
Study 30550987 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated illustrations without music/sounds
Number of subjects: 99
Study 30550987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no enhancements)
Number of subjects: 99
Study 27943260 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, one‐on‐one safe‐transportation program delivered by a registered occupational therapist in two sessions held approximately 1 month apart
Number of subjects: 380
Study 27943260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 380
Study 27943260 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized safe‐transportation program
Number of subjects: 380
Study 24917487 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention (HF)
Number of subjects: 2148
Study 24917487 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 2148
Study 24917487 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance dependence
Number of subjects: 2148